OPEN END TURBO OPTIONSSCHEIN SHORT - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 19:26:55 05/07/2024 BST | ||
| 2.56 EUR | -13.51% |
|
| Current month | +0.79% | ||
| 1 month | +29.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 2.56 | -13.51% |
| 04/07/24 | 2.96 | -3.90% |
| 03/07/24 | 3.08 | +19.84% |
| 02/07/24 | 2.57 | -10.76% |
| 01/07/24 | 2.88 | +13.39% |
Real-time BOERSE MUENCHEN
Last update July 05, 2024 at 07:26 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG1WE8 |
| ISIN | DE000GG1WE89 |
| Date issued | 05/01/2024 |
| Strike | 500.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.24 € |
|---|---|
| Lowest since issue | 1.6 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
